HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better
Founder and CEO Amit Etkin describes the independent academic work that has been published on this and explains how ALTO-207, which is a combination of pramipexole and ondansetron, appears to have a more tolerable profile. Plus, an update on two other key programs
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.